Shattuck Labs reports Q2 EPS (24c), consensus (25c)

Reports Q2 revenue $0 vs. $1.6M last year. As of June 30, 2025, cash and cash equivalents and investments were $50.5M vs. $105.3M as of June 30, 2024. The total anticipated proceeds from the oversubscribed private placement of up to approximately $103M, less offering expenses, combined with current cash and cash equivalents, are expected to fund operations into 2029. “Q2 of 2025 was a productive period for Shattuck, as we prepared and successfully submitted an IND application to the FDA,” said CEO Taylor Schreiber. “We expect to begin enrollment in our Phase 1 clinical trial, subject to regulatory alignment, in healthy volunteers later this quarter, and to complete the trial during the second quarter of 2026. Following our recent private placement, led by OrbiMed, we are in a strong position and expect to transition seamlessly into multiple Phase 2 clinical trials for our lead asset, SL-325, and fund our operations into 2029.”